Polyrizon Ltd.
PLRZNASDAQHealthcareBiotechnology

About Polyrizon

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

Company Information

CEOTomer Izraeli
Founded2005
IPO DateOctober 29, 2024
Employees6
CountryIsrael
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Corporate Identifiers

CIK0001893645
CUSIPM79549123
ISINIL0011814113
SIC3841

Leadership Team & Key Executives

Tomer Izraeli
Founder, Chief Executive Officer and Director
Nir Ben Yosef
Chief Financial Officer and Compliance Officer
Dr. Tidhar Turgeman
Chief Technology Officer
Dr. Eyal S. Ron Ph.D.
Chief Scientific Officer
Daphna Avital
Chief People Officer